Immune inflammation and disease progression in idiopathic pulmonary fibrosis

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Balestro, Elisabetta ^a   Calabrese, Fiorella ^a   Turato, Graziella ^a   Lunardi, Francesca ^a   Bazzan, Erica ^a   Marulli, Giuseppe ^a   Biondini, Davide ^a   Rossi, Emanuela ^a   Sanduzzi, Alessandro ^b   Rea, Federico ^a   Rigobello, Chiara ^a   Gregori, Dario ^a   Baraldo, Simonetta ^a   Spagnolo, Paolo ^a   Cosio, Manuel G ^a,c   Saetta, Marina ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD45 ANTIGEN; CD68 ANTIGEN;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; HUMAN TISSUE; INNATE IMMUNITY; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; QUANTITATIVE STUDY; RETROSPECTIVE STUDY; SPIROMETRY; SYMPTOMATOLOGY; AGED; IMMUNOLOGY; INFLAMMATION; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INFLAMMATION; MALE; MIDDLE AGED;

EID: 84969800141     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0154516     Document Type: Article

References (40)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824. doi: 10.1164/rccm.2009-040GL PMID: 21471066
2. Scadding JG, Hinson KF. Diffuse fibrosing alveolitis (diffuse interstitial fibrosis of the lungs). Correlation of histology at biopsy with prognosis. Thorax 1967; 22:291-304. PMID: 6035793
3. Katzenstein ALA, Myers JL. Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157:1301-1315. PMID: 9563754
4. Crystal RG, Bitterman PB, Rennard SI, Hance AJ, Keogh BA. Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract. N Engl J Med 1984; 310:154-166. PMID: 6361560
5. Ryu JH, Colby TV, Hartman TE. Idiopathic pulmonary fibrosis: current concepts. Mayo Clin Proc 1998; 73:1085-101. PMID: 9818046
6. Meier-Sydow J, Weiss SM, Buhl R, Rust M, Raghu G. Idiopathic pulmonary fibrosis: current clinical concepts and challenges in management. Semin Respir Crit Care Med 1994; 15:77-96
7. Selman M, Pardo A. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. Respir Res 2002; 3:3. PMID: 11806838
8. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134:136-151. PMID: 11177318
9. Wuyts WA, Agostini C, Antoniou KM, Bouros D, Chambers RC, Cottin V, et al. The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J 2013; 41:1207-18. doi: 10.1183/09031936.00073012 PMID: 23100500
10. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165:277-304. PMID: 11790668
11. American Thoracic Society; European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement. Am J Respir Crit Care Med 2000; 161:646-664. PMID: 10673212
12. Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3:285-292. PMID: 16738191
13. Selman M, Carrillo G, Estrada A, Mejia M, Becerril C, Cisneros J, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behaviour and gene expression pattern. PLoS One 2007; 2:e482. PMID: 17534432
14. Boon K, Bailey NW, Yang J, Steel MP, Groshong S, Kervitsky D, et al. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS One 2009; 4:e5134. doi: 10.1371/journal.pone.0005134 PMID: 19347046
15. Kahloon RA, Xue J, Bhargava A, Csizmadia E, Otterbein L, Kass DJ, et al. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med 2013; 187:768-75. doi: 10.1164/rccm.201203-0506OC PMID: 23262513
16. Gilani SR, Vuga LJ, Lindell KO, Gibson KF, Xue J, Kaminski N, et al. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS One 2010; 29;5(1).
17. Prasse A1, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009; 179:717-23. doi: 10.1164/rccm.200808-1201OC PMID: 19179488
18. Shinoda H, Tasaka S, Fujishima S, Yamasawa W, Miyamoto K, Nakano Y, et al. Elevated CC chemokine level in bronchoalveolar lavage fluid is predictive of a poor outcome of idiopathic pulmonary fibrosis. Respiration 2009; 78:285-92. doi: 10.1159/000207617 PMID: 19270434
19. Collard HR, Cool CD, Leslie KO, Curran-Everett D, Groshong S, Brown KK. Organizing pneumonia and lymphoplasmacytic inflammation predict treatment response in idiopathic pulmonary fibrosis. Histopathology 2007; 50:258-65. PMID: 17222255
20. DePianto DJ, Chandriani S, Abbas AR, Jia G, N'Diaye EN, Caplazi P, et al. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. Thorax 2015; 70:48-56. doi: 10.1136/thoraxjnl-2013-204596 PMID: 25217476
21. Nicholson AG, Fulford LG, Colby TV, du Bois RM, Hansell DM, Wells AU. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002; 166: 173-177 PMID: 12119229
22. Moore BB, Fry C, Zhou Y, Murray S, Han MK, Martinez FJ, et al. Inflammatory leukocyte phenotypes correlate with disease progression in idiopathic pulmonary fibrosis. Front Med 2014; 22;1(56). pii: 00056.
23. Taillè C, Grootenboer-Mignot S, Boursier C, Michel L, Debray MP, Fagart J, et al. Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183:759-66. doi: 10.1164/rccm.201001-0076OC PMID: 20935114
24. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176:636-43. PMID: 17585107
25. Ballarin A, Bazzan E, Zenteno RH, Turato G, Baraldo S, Zanovello D, et al. Mast cell infiltration discriminates between histopathological phenotypes of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186:233-9. doi: 10.1164/rccm.201112-2142OC PMID: 22679009
26. Bazzan E, Saetta M, Turato G, Borroni EM, Cancellieri C, Baraldo S, et al. Expression of the atypical chemokine receptor D6 in human alveolar macrophages in COPD. Chest 2013; 143:98-106. PMID: 22797410
27. Baraldo S, Turato G, Lunardi F, Bazzan E, Schiavon M, Ferrarotti I, et al. Immune activation in α1-antitrypsin-deficiency emphysema. Beyond the protease-antiprotease paradigm. Am J Respir Crit Care Med. 2015; 191:402-9. doi: 10.1164/rccm.201403-0529OC PMID: 25412116
28. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-82 doi: 10.1056/NEJMoa1402584 PMID: 24836310
29. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med 2014; 370:2083-92 doi: 10.1056/NEJMoa1402582 PMID: 24836312
30. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378:1949-61. doi: 10.1016/S0140-6736(11)60052-4 PMID: 21719092
31. Hunninghake GM. A New Hope for Idiopathic Pulmonary Fibrosis. N Engl J Med 2014; 370:2142-3 doi: 10.1056/NEJMe1403448 PMID: 24836311
32. Schmidt SL, Tayob N, Han MK. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest 2014; 145: 579-585 doi: 10.1378/chest.13-0844 PMID: 24231810
33. Song JW, Hong S- B, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011; 37:356-363. doi: 10.1183/09031936.00159709 PMID: 20595144
34. Parra ER, Karailla RA. Inflammatory cell phenotyping of the pulmonary interstitium in idiopathic interstitial pneumonia. Respiration 2007; 74:159-169 PMID: 17108669
35. Andersson CK, Andersson-Sjöland A, Mori M, Hallgren O, Pardo A, Eriksson L, et al. Activated MCTC mast cells infiltrate diseased lung areas in cystic fibrosis and idiopathic pulmonary fibrosis. Respiratory Research 2011; 12:139. doi: 10.1186/1465-9921-12-139 PMID: 22014187
36. Pardo A, Gibson K, Cisneros J, Richards TJ, Yang Y, Becerril C, et al. Up- Regulation and Profibrotic Role of Osteopontin in Human Idiopathic Pulmonary Fibrosis. PLoS Medicine 2005; 2:e251. PMID: 16128620
37. Vuga LJ, Tedrow JR, Pandit KV, Tan J, Kass DJ, Xue J, et al. C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014; 189:966-74. doi: 10.1164/rccm.201309-1592OC PMID: 24628285
38. Baran CP, Opalek JM, McMaken S, Newland CA, O'Brien JM Jr, Hunter MG, et al. Important Roles for Macrophage Colony-stimulating Factor, CC Chemokine Ligand 2, and Mononuclear Phagocytes in the Pathogenesis of Pulmonary Fibrosis. Am J Respir Crit Care Med 2007; 176:78-89. PMID: 17431224
39. Xue J, Kass DJ, Bon J, Vuga L, Tan J, Csizmadia E, et al. Plasma B Lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients.J Immunol 2013; 191:2089-95 doi: 10.4049/jimmunol.1203476 PMID: 23872052
40. Todd NW, Scheraga RG, Galvin JR, Iacono AT, Britt EJ, Luzina IG, et al. Lymphocyte aggregates persist and accumulate in the lungs of patients with idiopathic pulmonary fibrosis. J Inflamm Res 2013; 6:63-70. doi: 10.2147/JIR.S40673 PMID: 23576879